Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)

Market Cap	3.64B +15.2%
Revenue (ttm)	435.52M -0.5%
Net Income	52.06M +3.8%
EPS	0.48 +4.2%
Shares Out	108.29M
PE Ratio	69.54
Forward PE	n/a
Dividend	0.20 (0.61%)
Ex-Dividend Date	May 20, 2025

Volume	4,666,970
Average Volume	3,237,798
Open	31.28
Previous Close	31.47
Day's Range	31.28 - 33.05
52-Week Range	24.60 - 41.53
Beta	-1.58
RSI	61.33
Earnings Date	Apr 16, 2026

About SHE:301281

Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmolol hydrochloride; nicotinamide-tinidazole; amlexanox; nisoldipine; qupibutu; clarithromycin lactobionate; propafenone hydrochloride; potassium diclofe...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2004
• Employees: 696
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301281

Financial Performance

In 2024, SHE:301281's revenue was 463.72 million, an increase of 3.60% compared to the previous year's 447.58 million. Earnings were 60.27 million, a decrease of -21.76%.